Stephen J. Ubl

Stephen J. Ubl
Stephen J. Ubl is president and chief executive officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents American's leading biopharmaceutical research companies. The biopharmaceutical sector directly employs more than 854,000 Americans, and invests more than $90 billion in research and development every year - more than any other industry in America. Mr. Ubl leads PhRMA's work preserving and strengthening a health care and economic environment that encourages medical innovation, new drug discovery and access to life-saving medicines. Ubl is recognized around the world as a leading health care advocate and policy expert who collaborates successfully with diverse …
Stephen J. Ubl is president and chief executive officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents American's leading biopharmaceutical research companies. The biopharmaceutical sector directly employs more than 854,000 Americans, and invests more than $90 billion in research and development every year - more than any other industry in America.

Mr. Ubl leads PhRMA's work preserving and strengthening a health care and economic environment that encourages medical innovation, new drug discovery and access to life-saving medicines. Ubl is recognized around the world as a leading health care advocate and policy expert who collaborates successfully with diverse stakeholder groups - including patient and physician groups, regulators, public and private payers, and global trade organizations - to help ensure timely patient access to innovative treatments and cures. "If anyone can find areas of agreement with the critics, or at least work productively with them, it may be Mr. Ubl," the New York Times wrote in February 2016. "He is more conversant with the intricacies of health policy, and more adept at the politics."

As president and CEO of medical technology association AdvaMed, Ubl helped facilitate landmark reforms related to the U.S. Food and Drug Administration product review process and Medicare's coverage and reimbursement of medical technologies. He led the industry's defense of breakthrough R&D, successfully delaying an innovation-stifling device tax, and, in 2013, was recognized by a leading industry publication as one of 10 people to have a lasting impact on the medical technology industry.

Ubl has worked extensively with patient advocacy organizations in health policy, including longstanding service on the board of the National Health Council, a leading umbrella organization for voluntary health care organizations and has been personally involved with JDRF (formerly known as the Juvenile Diabetes Research Foundation).

He is routinely recognized as one of Washington's most effective advocates, and, in 2019, was named one of Business Insider's "DC Healthcare Power Players." He is consistently named to Modern Healthcare's "100 Most Influential People in Healthcare" list and is identified as a top health influencer by Medical Marketing & Media and PR Week magazines.

Prior to AdvaMed, Ubl was vice president of legislation for the Federation of American Hospitals. He began his Washington career on Capitol Hill.
See more

Articles: Stephen J. Ubl

The Inflation Reduction Act: What Needs Fixing & What’s Left to Address In Terms of Patient Affordability

USA / PhRMA President and CEO Stephen J. Ubl takes aim at the health insurers and pharmacy benefit managers (PBMs) driving medicines costs up in the US, and the Inflation Reduction Act (IRA) which he sees as failing to address the patient affordability conundrum. Ubl calls for a policy framework able to both support lifesaving innovation and…

USA: 2 Things the Biden Administration can do Now to Lower Costs at the Pharmacy

USA / PhRMA’s Stephen J. Ubl outlines two ways in which the new US presidency can help lower healthcare costs and why biopharmaceutical companies support changes to the system that can lower US patients’ out-of-pocket spending and continue to drive innovation.   By bringing an end to the pandemic and lowering out-of-pocket costs, our economy will finally…

PhRMA CEO on ‘Tireless’ Industry COVID-19 Response & Access Challenges Ahead

USA / Stephen J. Ubl, president and CEO of PhRMA, outlines the unprecedented collaboration and speed with which the biopharmaceutical industry has responded to the COVID-19 pandemic and the solutions that PhRMA is proposing to lower patient costs while protecting innovation and access.   We know that our innovation and our collaboration only count if what we…

See more